How to access Kerendia from the UAE, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Emirati patient with chronic kidney disease associated with type 2 diabetes (CKD in T2D) may receive a prescription for Kerendia (finerenone) from their treating nephrologist or cardio-renal specialist. Kerendia is FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalisation for heart failure in CKD associated with T2D. It is developed by Bayer. In the UAE, Kerendia availability through local supply is uneven across institutions; access is commonly coordinated through the named-patient pathway where a specific facility does not reliably stock it.
This guide explains the pathway, documentation your physician prepares, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Kerendia in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Kerendia is an oral non-steroidal selective mineralocorticoid receptor antagonist (MRA) taken once daily at 10 mg or 20 mg. Compared with steroidal MRAs (spironolactone, eplerenone), finerenone has a distinct selectivity profile and a hyperkalaemia-risk profile that requires structured potassium monitoring. Eligibility is anchored in documented CKD (typically uACR elevation and eGFR within labelled range) plus T2D. Your nephrologist establishes baseline potassium, eGFR, uACR, and sets the potassium-monitoring cadence.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Kerendia legally importable into the UAE?
Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, with parallel authority through the Department of Health (DoH) in Abu Dhabi and Dubai Health Authority (DHA) in Dubai depending on where the prescribing facility sits.
The mechanism permits an Emirati-licensed physician to import a medicine not routinely available at the institution when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is suitable and available at that institution, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented.
How the pathway works, step by step
- Consultation with your treating nephrologist or cardio-renal specialist. CKD documentation, T2D confirmation, potassium trajectory, and clinical rationale.
- Baseline assessment. eGFR, uACR, serum potassium, HbA1c, and potassium-monitoring plan.
- MoHAP named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, strength, and monitoring plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Kerendia from authorised distribution under DSCSA.
- Ambient shipment. Kerendia ships under controlled ambient conditions with chain-of-custody documentation.
- Arrival and dispensing. The hospital pharmacy releases the bottle to the patient with potassium-monitoring instructions.
What documentation your physician needs
- Clinical rationale letter confirming CKD-in-T2D indication and Kerendia as the indicated therapy
- Verification of the UAE medical license
- Baseline eGFR, uACR, serum potassium, HbA1c
- Potassium-monitoring cadence plan consistent with FDA labeling
- Planned dosing strength (10 mg or 20 mg) and titration plan
Reserve Meds provides a physician documentation kit bundling templates MoHAP reviewers expect for nephrology named-patient imports, including the potassium-monitoring plan central to Kerendia adherence.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, MoHAP documentation handling, and coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed pharmaceutical wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and MoHAP review.
- Logistics. Ambient-controlled shipment to your prescribing hospital.
- Dedicated case lead. A named point of contact coordinating monthly refills and monitoring reminders.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating nephrologist.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP / DoH / DHA named-patient framework with appropriate documentation. See our trust and compliance page.
How does Kerendia compare with spironolactone? Both are mineralocorticoid receptor antagonists, but Kerendia is non-steroidal and selective with a distinct hyperkalaemia and outcomes profile in CKD-T2D populations, supported by FIDELIO-DKD and FIGARO-DKD outcomes trials.
What monitoring is essential? Serum potassium before initiation, at 4 weeks, then periodically, your nephrologist sets the full cadence consistent with FDA labeling, including holding or titrating based on potassium.
Will insurance cover this? Cash-pay is the default for named-patient imports. Some UAE private insurers consider case by case; we supply documentation but do not process claims directly.
Recent regulatory and access news for Kerendia in the UAE
The Ministry of Health and Prevention (MoHAP) drug registration database at mohap.gov.ae has not added Kerendia to the registered products list over the last 12 months as of 2026-06-04. The Dubai Health Authority drug list at dha.gov.ae and the Department of Health Abu Dhabi formulary at doh.gov.ae have not added Kerendia to their formularies. Bayer continues commercial rollout of finerenone across the GCC with the FIDELIO-DKD and FIGARO-DKD evidence base supporting use in chronic kidney disease associated with type 2 diabetes; no UAE-specific licensing partnership announcement through Q1 2026. We update this section on each case file at intake; the snapshot date governs.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Kerendia in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Kerendia for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Kerendia in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Kerendia. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Kerendia in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Kerendia to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Kerendia to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Kerendia in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Kerendia in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.